How to cite item

Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics

  
@article{APS6679,
	author = {Jung-woo Bae and Chang-ik Choi and Mi-jeong Kim and Da-hee Oh and Seul-ki Keum and Jung-in Park and Bo-hye Kim and Hye-kyoung Bang and Sung-gon Oh and Byung-sung Kang and Hyun-joo Park and Hae-deun Kim and Ji-hey Ha and Hee-jung Shin and Young-hoon Kim and Han-sung Na and Myeon-woo Chung and Choon-gon Jang and Seok-yong Lee},
	title = {Frequency of  CYP2C9  alleles in Koreans and their effects on losartan pharmacokinetics},
	journal = {Acta Pharmacologica Sinica},
	volume = {32},
	number = {10},
	year = {2016},
	keywords = {},
	abstract = {Aim: CYP2C9 enzyme metabolizes numerous clinically important drugs. The aim of this study is to investigate the frequencies of CYP2C9 genotypes and the effects of selected alleles on losartan pharmacokinetics in a large sample of the Korean population.
Methods: The CYP2C9 gene was genotyped in 1796 healthy Korean subjects. CYP2C9 alleles (CYP2C9*1, *2, *3 and *13 alleles) were measured using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay and direct sequencing assay. The enzymatic activity of each  CYP2C9 genotype was evaluated using losartan as the substrate.
Results: The frequencies of CYP2C9*1, *3 and *13 allele were 0.952 (95% confidence interval 0.945–0.959), 0.044 (95% CI 0.037–0.051) and 0.005 (95% CI 0.003–0.007), respectively. The frequencies of the CYP2C9*1/*1, *1/*3, *1/*13 and *3/*3 genotypes were 0.904 (95% CI 0.890–0.918), 0.085 (95% CI 0.072–0.098), 0.009 (95% CI 0.005–0.013) and 0.001 (95% CI 0.000–0.002), respectively. In the pharmacokinetics studies, the AUC0–∞ of losartan in CYP2C9*3/*3 subjects was 1.42-fold larger than that in CYP2C9*1/*1 subjects, and the AUC0–∞ of E-3174, a more active metabolite of losartan, in CYP2C9*3/*3 subjects was only 12% of that in CYP2C9*1/*1 subjects.
Conclusion: The results confirmed the frequencies of CYP2C9 genotypes in a large cohort of Koreans, and detected the CYP2C9*3/*3 genotype. CYP2C9*3/*3 subjects metabolized much less losartan into E-3174 than CYP2C9*1/*1 subjects.},
	issn = {1745-7254},	url = {http://www.chinaphar.com/article/view/6679}
}